Bayer Detailed Consensus >> Segments
Last Update: 2021-02-03

Please note:

All 2019 figures were re-based to reflect the change in cost allocations from enabling functions to the divisions effective Jan. 1, 2020.


KPI[EUR m]Q4 2019FY 2019Q4 2020 EFY 2020 EFY 2021 EFY 2022 EFY 2023 EFY 2024 E
Pharmaceuticals, SalesNumber of Estimates161615141211
Pharmaceuticals, SalesHighest4,76417,53118,04819,15919,98119,557
Pharmaceuticals, SalesAverage4,68217,9624,48617,25317,55618,20718,25917,526
Pharmaceuticals, SalesMedian4,51917,28617,51318,20518,51617,538
Pharmaceuticals, SalesLowest4,08116,84816,81917,34816,69315,829
XareltoNumber of Estimates121212111111
XareltoHighest1,2764,5795,0405,3725,8205,700
XareltoAverage1,1484,1261,2204,5234,8235,0904,8693,771
XareltoMedian1,2244,5274,8005,0674,9863,721
XareltoLowest1,1304,4334,6554,8153,6872,660
EyleaNumber of Estimates121212111111
EyleaHighest6912,4902,7412,8323,0593,273
EyleaAverage6672,4946502,4492,5112,5292,5062,430
EyleaMedian6552,4542,5202,5452,4482,326
EyleaLowest5782,3772,2352,1912,2001,990
Mirena product familyNumber of Estimates111111111111
Mirena product familyHighest3081,1011,2271,2791,3301,370
Mirena product familyAverage3021,2232831,0761,1301,1521,1761,198
Mirena product familyMedian2871,0801,1381,1841,2301,260
Mirena product familyLowest2221,0151,060904814733
Kogenate (incl. Kovaltry, Jivi)Number of Estimates121212111111
Kogenate (incl. Kovaltry, Jivi)Highest301951989908927945
Kogenate (incl. Kovaltry, Jivi)Average222882205855828782750723
Kogenate (incl. Kovaltry, Jivi)Median204854825796763737
Kogenate (incl. Kovaltry, Jivi)Lowest84734648615590529
NexavarNumber of Estimates111111101010
NexavarHighest155635681481446419
NexavarAverage164706123603405282220186
NexavarMedian131611433291213156
NexavarLowest-1479116937460
Pharmaceuticals, EBITDA before special itemsNumber of Estimates161615141211
Pharmaceuticals, EBITDA before special itemsHighest1,5976,0746,1726,5526,7546,649
Pharmaceuticals, EBITDA before special itemsAverage1,4005,8611,4965,9735,9336,2076,2325,764
Pharmaceuticals, EBITDA before special itemsMedian1,5135,9905,9756,3426,4626,051
Pharmaceuticals, EBITDA before special itemsLowest1,2975,7745,5905,8465,3354,127
Consumer Health, SalesNumber of Estimates161615141211
Consumer Health, SalesHighest1,4495,2535,3695,4985,6305,765
Consumer Health, SalesAverage1,3375,4621,3225,1265,1665,3055,4485,591
Consumer Health, SalesMedian1,3325,1365,1815,3045,4585,613
Consumer Health, SalesLowest1,2265,0304,9745,0855,2045,327
Consumer Health, EBITDA before special itemsNumber of Estimates161615141211
Consumer Health, EBITDA before special itemsHighest4001,2551,2941,3631,3511,393
Consumer Health, EBITDA before special itemsAverage2991,1423091,1641,1921,2571,2951,343
Consumer Health, EBITDA before special itemsMedian3021,1571,1951,2641,3071,353
Consumer Health, EBITDA before special itemsLowest2801,1351,1181,1681,2301,267
CropScience, SalesNumber of Estimates161615141211
CropScience, SalesHighest4,58519,24918,82419,22219,90221,221
CropScience, SalesAverage4,65219,8324,11218,77618,29618,76619,30619,973
CropScience, SalesMedian4,15318,81718,40818,79119,46120,004
CropScience, SalesLowest3,60918,27317,17217,85818,57319,161
CropScience, EBITDA before special itemsNumber of Estimates161615141211
CropScience, EBITDA before special itemsHighest9584,9004,9745,2625,5785,981
CropScience, EBITDA before special itemsAverage8494,7147074,6494,4674,7965,0255,350
CropScience, EBITDA before special itemsMedian7454,6874,4704,8365,0045,408
CropScience, EBITDA before special itemsLowest1214,0634,0124,1904,3374,655
Reconciliation, SalesNumber of Estimates161615141211
Reconciliation, SalesHighest125295301307313319
Reconciliation, SalesAverage7928995265271273275276
Reconciliation, SalesMedian96266276278281287
Reconciliation, SalesLowest45215215215215215
Reconciliation, EBITDA before special itemsNumber of Estimates161615141211
Reconciliation, EBITDA before special itemsHighest497291421508508508
Reconciliation, EBITDA before special itemsAverage-73-245-54-260-248-216-219-214
Reconciliation, EBITDA before special itemsMedian-92-298-325-300-325-300
Reconciliation, EBITDA before special itemsLowest-188-394-450-450-625-745
Disclaimer

This document has been issued by Vara Research GmbH for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. The company did not participate in the compilation of the estimates and it does not endorse them. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Vara Research GmbH gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness.